GSK drug meets main goal in late-stage study to treat relentless itch
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected ...
pharmaphorum21d
Pruritus in PBC: Understanding its impact and the need for raising awareness
Chronic itch when living with PBC is attributed to ... I believe that empathising with people living with liver disease is an important factor in ensuring a good level of care.
What's Going On With Tharimmune Shares Monday?
Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented ...
Business Insider1d
Tharimmune presents clinical data on TH104 for chronic pruritus
Data presented at The Liver Meeting include adverse events as well as an assessment of patients’ relief of pruritus symptom scores when correlated to pharmacokinetics of TH104. Patients with ...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...